Legal & Pharma Regulation
U.S. Supreme Court Rejects Pharma Challenge to Drug Price Negotiation Law
What’s happening
The U.S. Supreme Court rejected a pharmaceutical industry challenge against a Biden-era Medicare drug pricing law.
What’s changing / Business impact
- Medicare retains power to negotiate some drug prices
- Increased pricing pressure on pharmaceutical companies
Why this matters
Historically, Medicare had limited power to negotiate drug prices directly.
This shows:
- government influence over pharmaceutical pricing is increasing
- the balance of power between pharma and regulators is shifting
CORE TAKEAWAY
Drug pricing power in the U.S. is gradually shifting away from pharma companies toward the government.